ATAI vs. IMCR, GLPG, AGIO, TWST, TARS, IDYA, CNTA, RXRX, INDV, and APGE
Should you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Immunocore (IMCR), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), Indivior (INDV), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.
Atai Life Sciences vs. Its Competitors
Immunocore (NASDAQ:IMCR) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.
Immunocore has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500.
84.5% of Immunocore shares are owned by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are owned by institutional investors. 10.4% of Immunocore shares are owned by insiders. Comparatively, 26.8% of Atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Atai Life Sciences has a net margin of 0.00% compared to Immunocore's net margin of -15.87%. Immunocore's return on equity of -12.84% beat Atai Life Sciences' return on equity.
Immunocore currently has a consensus target price of $58.89, suggesting a potential upside of 65.60%. Atai Life Sciences has a consensus target price of $8.67, suggesting a potential upside of 288.64%. Given Atai Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Atai Life Sciences is more favorable than Immunocore.
Atai Life Sciences received 261 more outperform votes than Immunocore when rated by MarketBeat users. However, 73.53% of users gave Immunocore an outperform vote while only 66.40% of users gave Atai Life Sciences an outperform vote.
In the previous week, Immunocore had 10 more articles in the media than Atai Life Sciences. MarketBeat recorded 11 mentions for Immunocore and 1 mentions for Atai Life Sciences. Atai Life Sciences' average media sentiment score of 1.29 beat Immunocore's score of 0.97 indicating that Atai Life Sciences is being referred to more favorably in the news media.
Atai Life Sciences has lower revenue, but higher earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Atai Life Sciences beats Immunocore on 11 of the 19 factors compared between the two stocks.
Get Atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atai Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ATAI) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ATAI Stock Free ATAI Stock Alerts